Clin2
NCT07424092Possibly a fitRecruiting

Virus injection for children with recurrent brain tumors

High Grade GliomaEpendymomaEmbryonal Tumor of BrainRecurrenceRefractoryPediatricYoung Adult

Treatments studied

Part of Cancer clinical trials.

This trial is testing a virus called DNX-2401, which is injected directly into the tumor, for children and young adults with high-grade brain tumors that have come back or are hard to treat. The goal is to see if this virus can shrink or control the tumor.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
39 people
Ages
1 year to 25 years
Study type
Interventional

Who can take part

  • You have a high-grade brain tumor (like glioblastoma, medulloblastoma, or ependymoma) that has come back or is not responding to treatment and cannot be fully removed by surgery.
  • You are between 1 and 25 years old.
  • You have at least one tumor that is bigger than about 1 cm and can be safely injected with a needle through a small hole in the skull.
  • You are in fairly good health, can take care of yourself, and your blood counts, kidney, and liver function are adequate.
  • You have not had chemotherapy, immunotherapy, or radiation to the whole brain or spine within the last 4–6 weeks, and you are off or on a low, stable dose of steroids.
  • If you are sexually active, you agree to use birth control for at least 3–4 months after treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06264388Recruiting· Phase 2
Gene therapy plus oral drug for recurrent brain tumors

This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.

Miami, Florida
NCT05096481Recruiting· Phase 2
Vaccine for brain tumors in children and young adults

This trial tests a vaccine that may help the immune system fight brain tumors (medulloblastoma, high-grade glioma, and DIPG). It is for patients who have already had standard treatment and whose tumors are still present or have returned.

Aurora, Colorado
NCT06519682Recruiting
Immunotherapy for young people with a specific brain tumor

This trial is testing a new immunotherapy (nivolumab) for children, teens, and young adults with a specific type of aggressive brain tumor (glioblastoma that has a DNA repair problem). It aims to see if giving this treatment early, right after surgery, can help the immune system fight the tumor.

Toronto, Ontario
NCT06126744Recruiting· Phase 1
Study of a virus therapy for recurrent brain cancer

This trial tests a virus-based treatment called MVR-C5252 for people whose high-grade glioma or glioblastoma has come back after standard therapy. The virus is injected directly into the tumor to try to kill cancer cells and boost the immune system. The goal is to see if it is safe and if it can shrink the tumor.

New York, New York
NCT03911388Recruiting· Phase 1
HSV G207 for Children with Recurrent Cerebellar Brain Tumors

This trial is testing a virus called HSV G207, which is injected directly into the tumor, to treat children and young adults with a type of brain tumor in the cerebellum that has come back or not responded to standard treatments.

Birmingham, Alabama
NCT06914479Recruiting· Phase 1
Gene therapy and valacyclovir for recurrent brain tumors in young people

This trial tests a new gene therapy that uses two special viruses and an oral antiviral drug (valacyclovir) to treat brain tumors that have come back in children and young adults. The therapy is given right after surgery to remove the tumor, with the goal of helping your immune system fight the cancer.

Ann Arbor, Michigan

Hear when a new High Grade Glioma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.